CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Faculdade de Ciências Farmacêuticas (FCF) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Graduated in Pharmacy-Biochemistry from the Federal University of Alfenas (EFOA / UNIFAL) (1999) and PhD in Pharmaceuticals and Medicines from the University of São Paulo (FCF / USP) (2003). Postdoctoral degree in Organic Synthesis by the State University of Campinas (UNICAMP) (2013). He is Associate Professor of the Faculty of Pharmaceutical Sciences of the University of São Paulo, where he coordinates the Laboratory of Design and Synthesis of Bioactive Substances (LAPESSB) of the Department of Pharmacy (FBF). He is Chair of the Course Coordination Commission (CoC) since 2015, acting as coordinator of the Pharmacy-Biochemistry course (FCF / USP). He is a member of the Coordinating Committee of the Postgraduate Program in Pharmaceuticals and Medicines (CCP / PPGFM) and a member of the PPGFM permanent advisory body. It concluded the orientation of 56 students, among them 8 master's dissertations, 4 doctoral thesis, besides undergraduation researchers, monographs of final course and mentoring. Responsible for undergraduate courses (Pharmaceutical Chemistry I and II) and Post-graduation (Mechanisms of Action of Drugs at Molecular and Electronic Levels) of FCF / USP. He has participated as an Effective Member of the Thematic Technical Committee of the Brazilian Common Denominations (CTT DCB) of the Brazilian Pharmacopoeia Commission (ANVISA) since 2012. Member of the Pharmaceutical Education Commission of the Regional Council of Pharmacy (CRF-SP). Member of the Brazilian Association of Pharmaceutical Education (ABEF). He has experience in the field of Pharmacy, with emphasis in Pharmaceutical Chemistry and Medicinal Chemistry, working mainly in the following subjects: planning and synthesis of bioactive compounds candidates for drugs and prodrugs, focusing on the treatment of infectious, neurodegenerative and cancer diseases; organic synthesis; drug laundering and pharmaceutical education. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Polypharmacology is emerging as an effective strategy for treating multifactorial diseases such as cancer. Hybrid inhibitors, capable of targeting two distinct pathways, have shown synergistic gains in treatment efficacy, mitigating the development of resistance. In our Lapessb laboratory, nanomolar-potent HDAC and micromolar-potent JAK3 hybrid inhibitors were developed, demonstrating ant…
Several studies pointed out the advantages of the multi-target approach in cancer treatment. In this context, the hybridization of pharmacophoric groups with distinct action can be a valuable strategy in the discovery of molecules capable of inhibiting two - or more - cellular signaling pathways, increasing the efficacy, and improving the therapeutic regimen of chemotherapy treatment. Pho…
Cancer is one of the leading causes of death worldwide. Recent studies reported that capsaicinoids, substances found in several species of peppers, have shown interesting antitumor activity by inducing selective apoptosis in tumors via TRPV receptors. Thus, the use of these compounds as structural models for the synthesis of analogues with potentially higher activity and lower toxicity is…
Currently, cancer is a leading cause of death worldwide. Although there are many drugs for cancer control, problems such as low selectivity and high toxicity stimulate the search for new antitumor molecules. Natural products have played an important role in the introduction of new drugs or even as molecular patterns in order to obtain new bioactive substances. Recent studies reported that…
Hematological cancers, such as leukemias and lymphomas, exhibit a high rate of resistance to conventional treatments, demanding new therapeutic approaches. This project proposes the development of hybrid inhibitors that simultaneously target HDAC6 and JAK3, proteins associated with tumor proliferation and therapy resistance. The originality of the proposal lies in the use of bioisosterism…
Cancer, the second leading cause of death worldwide, is characterized by the uncontrolled and disordered growth of cells that do not respond to programmed cell death mechanisms. Some types of cancer affect cells in the hematopoietic and lymphatic tissues and are called hematological malignancies. Due to their heterogeneous nature, these types of cancer often present remission, relapse, or…
Cancer, a complex disease, requires innovative treatment strategies, such as multi-target therapy, which seeks to maximize therapeutic efficacy by simultaneously attacking multiple biological targets. In this context, the focus on hybrid inhibitors, capable of acting on several targets and enhancing synergistic effects, has been gaining prominence, especially in the inhibition of HDACs an…
Several studies pointed out the advantages of the multi-target approach in cancer treatment. In this context, the hybridization of pharmacophoric groups with distinct action can be a valuable strategy in the discovery of molecules capable of inhibiting two - or more - cellular signaling pathways, increasing the efficacy, and improving the therapeutic regimen of chemotherapy treatment. Pho…
Several studies pointed out the advantages of the multi-target approach in cancer treatment. In this context, the hybridization of pharmacophoric groups with distinct action can be a valuable strategy in the discovery of molecules capable of inhibiting two - or more - cellular signaling pathways, increasing the efficacy, and improving the therapeutic regimen of chemotherapy treatment. Pho…
(Only some records are available in English at this moment)
Leukemias have low survival rates in Brazil, and the development of new treatments focused on overexpressed proteins in anticancer targets, such as kinases and HDACs, is crucial. Hybrid inhibitors that synergistically inhibit two different targets at once haves hown promising results in cancer treatment. However, maintaining selectivity is a challenge in multitargeting. This project aims …
| 1 / 1 | Ongoing grants |
| 4 / 3 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 11 / 9 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 19 / 16 | All research grants and scholarships |
| Associated processes | |